Torrent Pharmaceuticals Ltd Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Aman, on the India business, given our volume is declining when you mentioned that the chronic sales is pretty stable, how should I look at that versus the sales restructuring? I mean what was the reason behind the sales restructuring given the volume is already weak in the quarter -- over the last few months?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : This reduction that you've seen, were these essentially from any specific therapy areas or any particular brands, I mean the older brands, et cetera? Would you like to highlight?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Okay. Understood. And on the Brazil business, we have seen a good quarter-on-quarter momentum on a constant currency basis. Sanjay, what is the product launch pipeline for Brazil over the next year? And how should we look at growth in this market?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Understood. And lastly, on the operating cost, if I were to look at our other expenses ex R&D, that pretty much remains flat, even though commentary from most of the peers or even as you suggested near normalization of trends in India. Has the restructuring also meant lower SG&A cost? Is that the way you should look about it -- look at it? Or how should we look at this cost trending forward?